An injection device for protective embolic agent through the blood vessel cavity
By using a mixing device of temperature-sensitive phase change material and fluoroscopic developer in interventional treatment, a semi-gel-state protective embolizer is formed, which solves the problems of unstable dosage and inaccurate position in the prior art, and realizes interventional treatment The accuracy and safety of protective embolism improves the therapeutic effect.
Patent Information
- Application Number
- CN201911028538.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2019-10-28
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2039-10-28
AI Technical Summary
In the existing interventional treatment, protective embolizers have problems such as unstable dosage, inaccurate position, low reliability and accuracy during the bolus injection process, resulting in chemotherapy drugs or embolizing materials entering non-target blood vessels, resulting in ischemic necrosis and mistuning of the thrombus. Severe complications.
A device for injecting protective embolizers intravascular lumen was designed. By mixing the temperature-sensitive phase change material poloxamer with the fluoroscopic developer iodhell, it was designed to form a semi-gel state and then injecting it using heating-insulation. The box and refrigeration chamber control the status of the embolizer, ensuring accurate and safe protective embolization during interventional treatment and rapid recovery of blood flow after treatment.
It improves the accuracy of the dosage of protective embolizers and the controllability of the bolus injection process, ensures the accuracy of the embolization position, reduces the risk of mistuning, and enhances the effectiveness of interventional treatment and the long-term survival rate of patients.
Smart Images

Figure HDA0002249410830000011 
Figure HDA0002249410830000012 
Figure HDA0002249410830000013
Abstract
Description
Technical Field
[0001] The invention belongs to the field of medical technology and relates to an injection device for an embolic agent for interventional treatment, in particular to an injection device for an intravascular protective embolic agent. Background Art
[0002] Embolization, also known as embolotherapy, is a controlled injection of plugs into the blood vessels supplying the diseased organ through an arterial or venous catheter to block it and interrupt the blood supply in order to control bleeding, treat tumors and vascular lesions, and eliminate the function of the diseased organ. Embolization is an important technique in interventional therapy and one of the three major techniques in interventional radiology, and has become a major part of daily work.
[0003] With the development of interventional therapy and embolic materials and devices, trans-arterial embolization has become an important minimally invasive treatment method for a variety of benign and malignant diseases. It is defined as the injection of embolic materials through intravascular catheter technology to block the main trunk of the artery or its branches. The scope of treatment includes post-traumatic hemostasis, complications related to surgery or puncture, benign and malignant tumors of the liver and kidney, visceral aneurysms, arteriovenous malformations, refractory hypertension, and hemostasis treatment before tumor resection. According to the different sites of embolization, it can be divided into proximal embolization of the main embolic artery trunk and distal embolization of the embolic arteriole or capillary bed. Not only arterial embolism, but also venous embolism has more and more clinical application needs.
[0004] The concept of protective embolization is very important in the field of interventional therapy, but it is rarely mentioned because there is currently no suitable embolic material. Currently, it is only used to embolize some non-target blood vessels in order to achieve the purpose of temporary protection. However, coil embolization cannot restore distal blood flow in a short period of time, and the embolized local tissue still has the risk of ischemic necrosis or even perforation. In addition, even if the distal blood flow is restored through collateral circulation, the blood vessels embolized by coils still have a greater risk of occlusion in the long term, which will have an adverse effect on the next step of interventional treatment.
[0005] Interventional therapy plays a very important role in the comprehensive treatment of malignant tumors. Transarterial chemoembolization is an important means of minimally invasive interventional treatment of malignant tumors, but during the treatment process, it is often difficult to cannulate the tumor blood supply artery. If arterial chemoembolization is performed without accurate superselection of the tumor blood supply artery, it is bound to cause chemotherapy drugs and even embolic materials to enter normal tissues and cause damage, and it will also affect the treatment effect. In addition, during surgery, it is sometimes encountered that the tumor blood supply artery and the gallbladder, gastrointestinal tract and other hollow organs The blood supply artery is issued from the same trunk. At this time, if the tumor artery is not superselected due to the difficulty of cannulation, the embolic material will enter the tumor blood vessel and cause embolism to the hollow organ blood supply artery, thereby causing serious complications such as ischemia necrosis and even perforation.
[0006] If non-target blood vessels are temporarily and protectively embolized before chemoembolization, it is possible to prevent chemotherapy drugs and embolic materials from entering the non-target blood vessels. At the same time, the above protective embolization can restore blood flow in a short period of time after the tumor blood vessel embolization is completed, avoiding ischemic damage to non-target areas.
[0007] Existing protective embolic agents are composed of two parts: a temperature-sensitive phase change material (such as the temperature-sensitive gel material poloxamer) and an iodine contrast agent (such as iohexol, omnipaque, etc.). During interventional treatment, protective embolization can effectively reduce the damage to normal tissues caused by chemotherapy drugs or embolic materials, avoid or alleviate surgery-related complications, and is very practical.
[0008] The temperature-sensitive gel material poloxamer is a reversible temperature-sensitive gel material that is liquid at room temperature, and its state changes as the temperature rises, micellizing to form a colloid state, and reversibly transforms into a liquid as the temperature decreases. After the poloxamer gel is injected into the body, it maintains a colloid state under the human body temperature environment, forms a plug in the blood vessel cavity to achieve a transient embolism, and then transforms back into a liquid state in a short period of time (about 15 minutes), is metabolized and absorbed in the blood vessels for a short period of time, and then is excreted in the urine in the form of a prototype. In addition, lowering the temperature (such as by artificially injecting ice saline) can make the poloxamer gel reversibly become a liquid state, thereby shortening the phase change time. The half-life of poloxamer in the body is about 25 hours, so this property can be used as a vascular embolic agent for transient vascular embolism.
[0009] Poloxamer is injected into the body through a catheter in liquid form. As the body temperature rises, it micellizes into a colloidal state and forms an embolism in the blood vessel cavity. The formation of embolism makes it difficult to inject the embolic agent, resulting in the difficulty in controlling the injection volume and injection speed of the protective embolic agent during surgery. The dosage of the protective embolic agent is unstable, making it impossible to accurately control the position of the formed embolism, and the embolic agent cannot be injected into the targeted blood vessel. The injection dose cannot be flexibly adjusted according to the intraoperative situation to control the embolism length, and even leads to accidental embolism, thereby reducing the reliability and accuracy of the protective embolism, thereby affecting the full efficacy of the interventional therapy drugs and reducing the effectiveness of the interventional therapy.
[0010] At present, in the process of interventional treatment, it is often difficult to cannulate the tumor supply artery. If arterial chemoembolization is performed without accurate superselection of the tumor supply artery, it is bound to cause chemotherapy drugs and even embolic materials to enter normal tissues and cause damage, and it will also affect the treatment effect. In addition, during surgery, sometimes the tumor supply artery and the gallbladder, gastrointestinal tract and other hollow organs supply arteries are co-existing. At this time, if the tumor artery is not superselected due to the difficulty of cannulation, the embolic material will enter the tumor blood vessel and also cause embolism to the hollow organ supply artery, thereby causing serious complications such as ischemic necrosis or even perforation. If a temporary and protective embolization is performed on the non-target blood vessel before chemoembolization, it can prevent chemotherapy drugs and embolic materials from entering the non-target blood vessel. At the same time, the above-mentioned protective embolization can restore blood flow in a short time after the tumor blood vessel embolization is completed, avoiding ischemic damage to the non-target area. The "blockage" in the present invention is a temporary blockage, which is a protective blockage for the purpose of preventing permanent embolic agents from causing ectopic embolism, and will not cause ischemic damage. Summary of the invention
[0011] The purpose of the present invention is to provide an injection device for injecting a protective embolic agent through a blood vessel cavity in order to solve the technical problems existing in the protective embolic agent push injection process in the existing interventional treatment field. The injection device of the present invention fully utilizes the temperature-sensitive phase change characteristics of the protective embolic agent during the interventional treatment operation, increases the perspective visibility of the push injection process, and ensures that the protective embolic agent is carried out smoothly; it also ensures that the amount of the protective embolic agent is accurate, and the embolic position of the protective embolic agent in the non-target blood vessel where the therapeutic drug acts is accurate, thereby enhancing the reliability and accuracy of the protective embolic agent.
[0012] To achieve the purpose of the present invention, the present invention provides, on one hand, an injection device for a protective embolic agent through a blood vessel lumen during interventional treatment, comprising a mixing component, a heat preservation component and an injection component, wherein:
[0013] The mixing component is used to mix the temperature-sensitive phase-change material and the fluoroscopic developer to form a protective embolic agent;
[0014] The heat preservation component is used to heat the uniformly mixed protective embolic agent and keep it warm so that the protective embolic agent remains in a semi-gel state;
[0015] The injection assembly is used to push the protective embolic agent in a semi-gel state into the blood vessel cavity that needs to be temporarily blocked, temporarily blocking the blood vessel and playing a protective embolic role.
[0016] Wherein, the temperature-sensitive phase change material is poloxamer 407; the fluoroscopic developer is iohexol, iodixanol, iopromide or iopamidol, preferably iohexol.
[0017] In particular, the temperature-sensitive phase change material is a 20% aqueous solution of poloxamer 407; and the fluoroscopic developer is iohexol injection.
[0018] In particular, the volume ratio of the temperature-sensitive phase change material to the fluoroscopic developer is 4:1, that is, the volume ratio of 20% poloxamer to iohexol injection is 4:1.
[0019] Among them, the injection component and the mixing component are detachably connected, and the evenly mixed embolic agent in the mixing component is injected into the injection component; the insulation component heats and insulates the evenly mixed protective embolic agent placed in the injection component, so that the embolic agent injected into the injection component is in a semi-gel state; when performing an interventional surgery, the injection component is taken out, and the embolic agent is injected into the blood vessel cavity that requires temporary embolization through the injection component. After the surgery is over, rescue saline is injected through the injection component to liquefy the protective embolic agent and restore blood flow.
[0020] Wherein, the mixing assembly includes 2 mixers and 1 connecting piece, the connecting piece includes 3 connecting branches, and the 3 connecting branches are interconnected; wherein the connecting ends of the first and second connecting branches are detachably connected to the 2 mixers respectively, and the connecting end of the third connecting branch is detachably connected to the injection assembly.
[0021] Among the two mixers, the volume of the first mixer is greater than the volume of the second mixer.
[0022] Particularly, the temperature-sensitive phase change material is placed in the first mixer, and the perspective developer is placed in the second mixer.
[0023] In particular, the volume ratio of the first mixer to the second mixer is 3-5:1, preferably 4:1.
[0024] Particularly, the first and second mixers are selected from screw-mouth syringes and disposable medical syringes, preferably screw-mouth syringes, and more preferably ring-handle screw-mouth syringes.
[0025] The connection ends of the three connecting branches have threads, usually internal threads, which are threadedly connected to the first and second mixers and the injection assembly, respectively.
[0026] In particular, a valve is provided on the third connecting branch of the connecting piece to control the flow direction of the evenly mixed protective embolic agent.
[0027] The connecting piece is used to connect the injection component with the mixing component, and the temperature-sensitive phase change material and the perspective developer placed in the mixing component are mixed to form a protective embolic agent, which is then injected into the injection component.
[0028] The connecting piece is a three-way connecting pipe in the shape of a "Y" or "T" or Type or type.
[0029] Particularly, the connector is a three-way tube for infusion (ie a three-way tube for medical infusion).
[0030] A valve is arranged near the end of the third connecting branch of the connecting piece to control the flow direction of the mixed temperature-sensitive phase-change material and the fluoroscopic developer in the first and second mixers.
[0031] A valve is set at the head end of the third connecting branch tube, and poloxamer and iohexol enter the third connecting branch tube through the first connecting branch tube and the second connecting branch tube to be mixed, and then the valve is turned to connect the third connecting branch tube with the injection component, and the evenly mixed protective embolic agent is pushed into the injection component.
[0032] The ends of the three connecting branches of the connecting piece have threads, usually internal threads, which match the threads of the first and second mixers and the injector.
[0033] In particular, the first and second connecting branch pipes are fixedly connected (threadedly connected) to the injection joints of the first and second mixers respectively; and the third connecting branch pipe is fixedly connected to the injection assembly.
[0034] Wherein, the injection assembly includes a pusher and an embolism rescue component, wherein the pusher includes at least one pusher for placing and pushing the protective embolic agent; the embolism rescue component is a rescue syringe for placing and pushing physiological saline.
[0035] In particular, the number of the push injectors is preferably 1-3, preferably 2-3.
[0036] In particular, the sizes and shapes of the injectors may be the same or different.
[0037] In particular, the volume of the first of the two injectors is greater than the volume of the second injector.
[0038] In particular, the first syringe has a size of 5 ml and the second syringe has a size of 2 ml.
[0039] Among them, the pusher and rescue syringe are selected from screw-mouth syringes and disposable medical syringes, preferably screw-mouth syringes, and more preferably screw-mouth ring-handle syringes.
[0040] In particular, the injector is detachably connected to the third connecting branch of the connecting piece of the mixing assembly.
[0041] In particular, the injector is threadedly connected to the third connecting branch pipe.
[0042] In particular, the injection assembly also includes a microcatheter, which is connected to a pusher or a rescue syringe. When the microcatheter is connected to the pusher, the protective embolic agent in the pusher is pushed into the blood vessel cavity that requires temporary protective embolism; when the microcatheter is connected to the rescue component, the physiological saline in the rescue syringe is pushed into the blood vessel cavity that has undergone protective embolism, thereby accelerating the conversion of the protective embolic agent into a liquid state and releasing the embolism.
[0043] In particular, the microcatheter is a superselective microcatheter, ie a superselective microcatheter used in interventional treatment.
[0044] Particularly, the tail end of the microcatheter has a thread, which is threadedly connected to the first and second injectors or the rescue syringe.
[0045] Particularly, the microcatheter is detachably connected to the pusher and the rescue syringe.
[0046] The pushers are used to load protective embolic agents, the difference being that the first pusher has a specification of 5 ml and the second pusher has a specification of 2 ml. The rescue syringe is used to load ice / room temperature saline, which can accelerate the process of the mixture of poloxamer 407 and iohexol transforming from a colloidal state to a liquid state, thereby relieving the protective embolic state in advance.
[0047] Wherein, the insulation component includes a heating-insulation box with heating and insulation functions and a refrigeration box with refrigeration function, and the injection component is placed inside the heating-insulation box and the refrigeration box.
[0048] The heat preservation component is heated to the phase transition temperature of the protective embolic agent and maintained at the phase transition temperature, so that the protective embolic agent remains in a semi-gel state.
[0049] In particular, the pusher part of the injection component is placed in a heating and insulation box, and the pusher part is heated and insulated so that the protective embolic agent placed in the pusher part is maintained at the phase change temperature; the embolic rescue part of the injection component is placed in a refrigerator so that the embolic rescue part is maintained at a low temperature or room temperature.
[0050] In particular, the heating and insulated box keeps the protective embolic agent placed in the pusher at 37.0±0.5°C; the refrigerated box keeps the temperature of the physiological saline placed in the rescuer at 5±0.5°C.
[0051] Among them, the heating-insulation box includes a box body, a partition and an electric heating element. The partition is arranged inside the box body to divide the box body into two parts, an upper part and an lower part. A heating chamber is enclosed between the box body and the lower part of the partition. The box body is lined with insulation material. An electric heating element is arranged in the heating chamber enclosed by the box body and the partition. The electric heating element is equipped with an electronic heating controller.
[0052] In particular, the electric heating element is an existing and known heating device in the art, such as an electric heating tube, a heating wire, a resistance wire, etc. All electric heating elements known in the art are suitable for the present invention.
[0053] The electronic heating controller can set the temperature to be heated and maintained as needed.
[0054] The heating and insulation box can adjust the heating and insulation temperature of the heating and insulation box at any time according to the needs of use; and after the temperature of the heating and insulation box is set, the temperature inside the box is maintained within the range of ±0.5℃. For example, if the heating temperature is set to 37℃, the heating and insulation box will maintain the temperature at 37.0±0.5℃ after heating, and other temperatures are similar.
[0055] Wherein, at least one injector groove is provided on the partition of the heating-insulation box for accommodating and placing the injector of the injection assembly.
[0056] In particular, the partition is provided with 1-3 independent syringe grooves, which are respectively used to accommodate and place the syringes of the injection assembly 1-3; preferably, there are 2-3 syringe grooves.
[0057] In particular, the size and shape of the pusher groove match the size and shape of the pusher of the injection assembly, respectively.
[0058] In particular, the box body of the heating-insulation box has an openable and closable closing cover for closing the insulation box to prevent the loss of heating heat and maintain a constant temperature inside the box.
[0059] Wherein, the cold storage box is a medical cold storage box used for placing and fixing the rescue syringe.
[0060] In particular, the temperature of the refrigerator is adjusted to 5±0.5° C. In particular, a rescue syringe groove for fixing the rescue syringe is provided in the refrigerator, and the size and shape of the rescue syringe groove match the size and shape of the rescue syringe of the injection assembly.
[0061] When the embolism rescue syringe is filled with saline, it is placed and fixed in the refrigerator of the insulation component to cool down and maintain at 5±0.5℃. After the angiography confirms that the tip of the microcatheter is located in the non-lesion supplying artery that has been protectively embolized, ice saline can be injected to accelerate the liquefaction of the protective embolic agent and restore arterial blood flow in advance.
[0062] The refrigerator uses chip refrigeration technology (semiconductor refrigeration / electronic refrigeration), with a refrigeration temperature of 2-25°C, preferably 2-8°C.
[0063] The mixing component of the device of the present invention is used to place the temperature-sensitive phase change material and the fluoroscopic developer respectively, and after the temperature-sensitive phase change material and the fluoroscopic developer are evenly mixed, they are pushed into the pusher of the injection component; when the push syringe is filled with the protective embolic agent, it is placed in the heating-insulating box of the insulation component, heated and kept warm at 37.0±0.5°C, so that the protective embolic agent is in a semi-gel state; physiological saline is placed in the embolic rescue syringe, placed in the refrigerator of the insulation component, and kept at 5±0.5°C.
[0064] When performing protective embolization, first push the protective embolic agent into the non-lesion supplying artery that needs temporary protection to embolize the non-lesion supplying artery; that is, during interventional treatment, after the angiography confirms that the tip of the microcatheter is located in the non-lesion supplying artery that needs protection, according to the arterial diameter and flow rate, take out the corresponding specification pusher from the insulation component, connect it to the tail end of the microcatheter through the screw at the head end, and push the protective embolic agent into the non-lesion supplying artery that needs protection under fluoroscopy; after embolization, conventional chemotherapy embolization can be performed. There are two situations in which a rescue syringe may be needed during the interventional surgery: 1. When the protective embolic agent is injected too much or the blockage site is not good, superselect the microcatheter to the proximal end of the rubber plug, take out the rescue syringe containing ice / room temperature saline from the insulation component, connect it to the tail end of the microcatheter through the screw at the head end, and push the saline to accelerate the liquefaction of the embolic agent blocking the blood vessel cavity, relieve the embolism, and restore blood flow; 2. The time for the protective embolic agent of the present invention to naturally transform into a liquid state and relieve the embolism is about 15 minutes. Therefore, if the conventional chemoembolization operation goes smoothly (i.e., the conventional chemoembolization operation is shorter than 15 minutes), after the chemoembolization operation is completed, the microcatheter can be superselected to the proximal end of the rubber plug, and the rescue syringe filled with ice / room temperature saline can be taken out from the insulation component and then connected to the microcatheter. The saline is continuously injected to accelerate the liquefaction of the embolic agent blocking the blood vessel lumen and release the protective embolism of the non-lesion supplying arteries in advance.
[0065] The present invention can also directly push and inject room temperature physiological saline. First, the microcatheter head end is superselected to the non-lesion blood supply artery that needs temporary protection through the vascular superselection technology, and the blood flow is ensured to be smooth; then the pusher of the injection component is taken out from the insulation component, and connected to the tail end of the microcatheter through the screw port; then, after confirming that the head end of the microcatheter is located in the non-lesion blood supply artery that needs protection under fluoroscopy, the injection is slowly pushed; if the protective embolism needs to be released in advance, the microcatheter can be selected again to the temporarily protected artery, and the embolism rescue syringe filled with low-temperature physiological saline is connected to the tail end of the microcatheter through the screw port, and the protective embolic agent is accelerated to be converted into a liquid state by injecting low-temperature or room temperature physiological saline, thereby releasing the embolism.
[0066] Compared with the prior art, the device for injecting protected embolic agents of the present invention has the following advantages:
[0067] 1. The device for injecting protective embolic agents into the blood vessel lumen of the present invention can accurately push the protective embolic agents to the location of the blood vessel to be blocked as determined by imaging methods, and can be directly used during interventional surgical treatment.
[0068] 2. The device for injecting the protective embolic agent into the blood vessel cavity of the present invention preheats the protective embolic agent in advance, thereby preventing the poloxamer from being carried away by the blood flow in the process of slowly heating up and forming a plug in the blood vessel as the blood flows after injection at low temperature, causing the protective embolic agent to drift in position, resulting in the uncontrollable process of the dosage and injection speed of the protective embolic agent, the dosage is unstable, and the position of the formed embolism cannot be accurately controlled, thereby reducing the reliability and accuracy of the protective embolism, thereby affecting the full efficacy of the interventional treatment drugs and reducing the effect of the interventional treatment, greatly improving the stability, accuracy and operability of the protective embolism process, and also limiting its dosage within a safe and controllable range, and also avoiding the risk of misembolization to the greatest extent;
[0069] 3. Usually, since the thermosensitive phase change material (such as poloxamer 407) is not visible under fluoroscopy, simple injection of the thermosensitive phase change material may cause reflux and the like, making the injection process uncontrollable and reducing the reliability and accuracy of protective embolism. The device is provided with an injection syringe containing iodine contrast agent for fluoroscopic development, which can be mixed with the thermosensitive material during the operation and then injected into the blood vessel, thereby ensuring the characteristics of the thermosensitive phase change material and increasing the visibility of the thermosensitive phase change material under fluoroscopy, thereby ensuring the smooth progress of protective embolism.
[0070] 4. The device for injecting the protective embolic agent into the blood vessel lumen of the present invention appropriately heats the protective embolic agent before injection, so that the protective embolic agent is in a semi-gel state between liquid and gel, has fluidity, and is convenient for injection. At the same time, because it is in a semi-gel state, it can quickly form a gel after being injected into the blood vessel, reducing its fluidity in the blood vessel, and accurately positioning it in the blood vessel that needs embolization, thereby achieving the effect of targeted injection, that is, the injection device directly injects the protective embolic agent into the targeted blood vessel position, flexibly adjusts the injection amount according to needs, controls the duration of embolization, and is easy to operate.
[0071] 5. Currently, there are no ultra-short-term embolic agents specifically used for protective embolization in the interventional field. The recanalization time of existing short-term embolic agents is also about 10 days. Although using such embolic agents to embolize non-target blood vessels in advance can achieve the purpose of blocking drugs or embolic materials from entering non-target blood vessels, the excessively long recanalization time causes irreversible ischemic damage to the local area. Therefore, it cannot meet the requirements of "protective embolization" and cannot play a protective role.
[0072] The protective embolic agent injected by the device of the present invention can ensure the restoration of blood flow in a short time after embolism, ensure that non-target blood vessels are not affected by drugs or embolic materials, avoid the occurrence of ischemic damage in non-target areas, and ensure the long-term patency of the local blood vessels that are protectively embolized.
[0073] 6. During interventional treatment, if the protective embolic agent is injected in liquid form, although the injection is smooth, there are problems such as excessive injection due to too little resistance, poor controllability, and unstable dosage; or it drifts with the blood flow, causing accidental embolism; and if it is injected in colloidal form, the absorption process is difficult, resulting in inaccurate absorption and inconvenient use.
[0074] In the protective embolic agent injection device of the present invention, the embolic agents of poloxamer and contrast agent respectively placed in the mixing component are first sucked into the pusher of the injection component through the connecting piece through the mixing component, and then the pusher is placed in the insulation component. Before being injected into the blood vessel, the embolic agent material is heated in the insulation component and maintained at 37±0.2°C, so that the embolic material is converted from a liquid state to a semi-gel state, and then the protective embolic material in the semi-gel state is pushed through the injection component to the position of the blood vessel that needs to be blocked determined by a medical imaging method.
[0075] During interventional surgery, the injection assembly is connected to the superselective microcatheter, and the protective embolic agent in a semi-gel state is pushed into the blood vessel cavity. The protective embolic agent is pushed while maintaining a colloidal state, which overcomes the problems of poor controllability and unstable dosage of liquid embolic materials during the push injection process. In addition, the controllability of the embolic material push injection is improved, the dosage is accurate, and the accuracy of the embolic position is improved, that is, the accurate positioning of the embolic position of the embolic agent during interventional treatment is improved, thereby improving the efficacy of the therapeutic drug and prolonging the patient's long-term survival. Compared with the direct use of liquid poloxamer, this change greatly improves the stability of the protective embolic push injection process, the accuracy of the embolic blood vessel position after the embolic material is pushed, and the operability, while also limiting its dosage to a safe and controllable range.
[0076] 7. In the device of the present invention, the protective embolic material is absorbed in the form of liquid, and the phase change material poloxamer and the fluoroscopic developer iohexol are respectively injected into the first and second mixers of the mixing component in liquid form. The volume of injection and absorption is accurate, and the amount of the phase change material and the fluoroscopic developer is accurate. The embolic material is easy to take, and the problem of the difficulty in taking the protective embolic material is overcome.
[0077] The injection device for the protective embolic agent through the vascular cavity of the present invention fills the gap in the protective embolic agent in the field of interventional treatment. Its characteristics include X-ray development characteristics, biological safety, reversible occlusion of blood vessels without vascular damage, etc. After integrating the ring-handled syringe and the heating device, it can be directly used during the interventional treatment operation.
[0078] The application prospects of the injection device of the present invention are broad, and representative procedures include transarterial chemoembolization, which has been carried out for the longest time and has the largest number of cases in the field of tumor interventional treatment, including chemoembolization for solid tumors in various parts of the body represented by liver and kidney. In addition, due to the rich vascular network and complex branches in the pelvic cavity, the application prospects of the device in pelvic artery chemoembolization are also broad; among them, bladder artery chemoembolization for the treatment of bladder malignant tumors and prostate artery embolization for the treatment of benign prostatic hyperplasia, which is emerging in China, are representative.
[0079] Judging from the current status and development trend of interventional treatment of tumors in China, among all the surgeries of intra-arterial tumor interventional treatment, at least 30% will be able to or need to adopt the innovative method of "protective embolization" to improve the efficacy. The protective embolic agent injection device of the present invention improves the accurate positioning and stability of the embolic position of the embolic agent during the interventional treatment of tumors, improves the efficacy of tumor treatment drugs, and prolongs the long-term survival of tumor patients in my country. BRIEF DESCRIPTION OF THE DRAWINGS
[0080] Figure 1 This is a schematic structural block diagram of the use of the intravascular protective embolic agent injection device of the present invention;
[0081] Figure 2 It is a schematic diagram of the structure of a mixing component of the device for injecting protective embolic agents through the vascular cavity of the present invention;
[0082] Figure 3 It is a schematic diagram of a first injector in the injection assembly of the protective embolic agent injection device of the present invention;
[0083] Figure 4 It is a schematic diagram of the heating-insulating box structure of the insulation component of the protective embolic agent injection device of the present invention;
[0084] Figure 5 It is a structural schematic diagram of another embodiment of the heating-insulating box of the insulation component of the protective embolic agent injection device of the present invention;
[0085] Figure 6 The present invention is a schematic diagram of the electrical principle of controlling the temperature of the heating-insulation box of the insulation component of the device of the present invention.
[0086] Description of reference numerals:
[0087] 1. First mixer; 2. Second mixer; 3. Connector; 31. First connecting branch; 32. Second connecting branch; 33. Third connecting branch; 4. Valve; 5. Heating-insulation box; 51. Box body; 52. Sealing cover; 53. Partition; 54. Electric heating element; 55. Heating chamber; 56. Heating temperature controller; 7. First injector groove; 8. Second injector groove; 9. Third injector groove; 10. Rescue injector groove; 11. Injector; 20. Mixing assembly; 30. Insulation assembly; 40. Injection assembly. DETAILED DESCRIPTION
[0088] The present invention will be further described below in conjunction with specific embodiments, and the advantages and features of the present invention will become clearer as the description proceeds. However, these embodiments are exemplary only and do not constitute any limitation to the scope of the present invention. It should be understood by those skilled in the art that the details and forms of the technical solution of the present invention may be modified or replaced without departing from the spirit and scope of the present invention, but these modifications and replacements all fall within the scope of protection of the present invention.
[0089] The present invention explores the establishment of an integrated protective embolization device for interventional therapy. The team explored the feasibility of mixing poloxamer 407 with non-ionic iodine contrast agents, established a protective embolization model, and used the invented "intra-arterial protective embolization device" for embolization.
[0090] Figure 1 Schematic diagram of the protective embolic agent injection device through the vascular cavity in the interventional treatment of the present invention, such as Figure 1As shown, the device includes a mixing component 20, a heat preservation component 30 and an injection component 40. The protective embolic agent uniformly mixed by the mixing component is injected into the injection component, and then the injection component is placed in the heat preservation component for heating and heat preservation, so that the protective embolic agent is in a semi-gel state; when the interventional surgery is to be performed, the injection component is taken out from the heat preservation component, and the protective embolic agent in the injection component is injected into the blood vessel cavity that needs protective embolization to achieve temporary embolization, thereby playing a role in protecting non-tumor blood supply vessels and non-target blood vessels during interventional treatment.
[0091] 1. The mixing component is used to mix poloxamer and fluoroscopic contrast agent to form a protective embolic agent.
[0092] The protective embolic agent is composed of a thermosensitive phase change material and a fluoroscopic developer, wherein the thermosensitive phase change material is poloxamer 407; the fluoroscopic developer is a non-ionic iodine contrast agent, preferably iohexol. The mass volume fraction of the poloxamer aqueous solution in the protective embolic agent is 16%-18% (w / v).
[0093] A 20% poloxamer 407 aqueous solution is mixed with an iohexol injection to prepare a poloxamer-iodine contrast agent mixed solution with a mass volume concentration of 16%-18% (w / v) of the poloxamer 407 aqueous solution, which is the protective embolic agent of the present invention. The protective embolic agent of the present invention (i.e., a mixture in which the mass volume fraction of the poloxamer aqueous solution in the poloxamer-iohexol mixture is 16%-18% w / v) has a phase transition temperature of 37.0±0.5°C and is suitable for in vivo experiments as an embolic agent.
[0094] In the embodiment of the present invention, the protective embolic agent includes 20% poloxamer 407 aqueous solution and iohexol injection, wherein the volume ratio of 20% poloxamer 407 aqueous solution to iohexol injection is 4:1. The phase transition temperature of the protective embolic agent used in the embodiment of the present invention is 37°C.
[0095] The temperature-sensitive gel material poloxamer in the present invention is a reversible temperature-sensitive gel material, which is liquid at room temperature, and changes its state as the temperature rises, forming micelles to form a colloid state, and reversibly turns into a liquid as the temperature decreases. In the present invention, poloxamer 407 is mixed with the fluoroscopic developer iohexol for protective embolization in interventional treatment, which has good controllability and stability. Animal experiments show that the semi-gel state formed when the mixture is heated to 37°C can not only ensure smooth pushing, but also enable the mixture to quickly form a gel plug after entering the body, thereby playing a protective role.
[0096] The protective embolic agent of the present invention maintains a colloid state under human body temperature, forms a plug in the blood vessel cavity to achieve short-term embolism, and then changes back to a liquid state in a short time (about 15 minutes), completely restores blood flow (has been verified by animal experiments), is metabolized and absorbed in the blood vessel in a short time, and then is excreted in the urine in the form of a prototype. In addition, lowering the temperature (such as by artificially injecting ice saline) can make the embolic agent reversibly change from a gel to a liquid state, shorten the phase change time, and restore blood flow in a short time.
[0097] like Figure 2 The mixing assembly includes a first mixer 1, a second mixer 2 and a connector 3, wherein the connector is a three-way connecting pipe including three connecting branches 31, 32 and 33, and the three connecting branches are interconnected to form a "Y" shape, a "T" shape or a Type or The connecting ends of two of the connecting branches of the connecting piece are detachably connected to the first and second mixers, respectively, and the connecting end of the third connecting branch is detachably connected to the injection assembly. The connecting ends of the three connecting branches have threads (not shown in the drawings), usually have internal threads, and are respectively connected to the first and second mixers and the injection assembly by threads. The first connecting branch 31 is threadedly connected to the first mixer; the second connecting branch 32 is threadedly connected to the second mixer; and the third connecting branch 33 is threadedly connected to the injection assembly.
[0098] The first mixer contains a temperature-sensitive phase-change material (i.e., a 20% poloxamer 407 aqueous solution); the second mixer contains a fluoroscopic developer (i.e., an iohexol injection). The first and second mixers use screw-mouth syringes, and the empty barrels of the syringes are marked with scales showing the volume of the liquid in the barrels, wherein the ratio of the volume of the first mixer to the volume of the second mixer is 4:1, the first and second mixers have the same height, and the ratio of the diameter of the first mixer to the diameter of the second mixer is 2:1.
[0099] A valve 4 is provided near the end of the third connecting branch pipe to adjust the flow direction of the uniformly mixed protective embolic agent. Figure 2 . Turn the valve to connect the third connecting branch with the injection assembly, push the first and second mixers, inject the temperature-sensitive phase change material and the fluoroscopic developer into the third connecting branch through the first and second connecting branches of the connector, and mix the temperature-sensitive phase change material and the fluoroscopic developer evenly in the third connecting branch to form a protective embolic agent, which is then injected into the injection assembly. After the required injection dose for the operation is reached, turn the valve again to close the invention and stop injecting the protective embolic agent into the injection assembly; then remove the injection assembly injected with the embolic agent from the third connecting branch of the mixing assembly, place it in the insulation assembly for heating and insulation, so that the protective embolic material is kept at 37.0±0.5°C in a semi-gel state for standby use.
[0100] The valve may also be a three-way valve, which is mainly used to prevent the protective embolic agent from overflowing and causing unnecessary losses. The check valve commonly used in clinical practice to guide the flow direction is the three-way valve for infusion. In this device, the three-way valve for infusion is usually placed in a closed state to prevent the overflow of iohexol or poloxamer 407. When the protective embolic agent needs to be prepared, the three-way valve is adjusted to an open state, and then the first and second mixers are pushed to allow iohexol and poloxamer 407 to enter the injection device in a ratio (i.e., 1:4) through the connecting branch.
[0101] In the specific implementation of the present invention, the first and second mixers are respectively selected from 20ml and 5ml ring-handle screw-mouth syringes. The connecting branch is a medical PVC material tube; the connecting piece is a tee for infusion (ie a medical infusion tee tube).
[0102] All syringes in the device of the present invention are selected from ring-handle screw-mouth syringes, and the syringes are respectively provided with corresponding scales for marking the dosage. In addition to screw-mouth syringes, other types of syringes in the art are applicable to the present invention, such as disposable medical syringes.
[0103] 2. The injection component is used to push the protective embolic agent maintained in a semi-gel state into the blood vessel cavity that needs to be temporarily blocked during interventional treatment, temporarily blocking the blood vessel and playing a protective embolic role.
[0104] The protective embolic agent pushed into the blood vessel cavity reaches a phase transition temperature of 37°C in vivo, and changes from a semi-gel state to a gel state, temporarily blocking non-lesion blood supply vessels. The protective embolic agent of the present invention naturally changes to a liquid state in about 15 minutes, and after the latter 15 minutes, the blood flow in the blocked blood vessel is restored to be unobstructed, thereby playing a protective embolic role. In addition, continuous push injection using ice / room temperature saline can accelerate the process of the protective embolic agent being converted to a liquid state, and remove the protective embolism of non-lesion blood supply arteries in advance. After the protective embolic agent in a gel state is converted into a liquid state, no debris will be generated to cause secondary embolism to the distal blood vessels.
[0105] The injection assembly includes a pusher, an embolism rescue component and a microcatheter (not shown in the figure), wherein the pusher includes three pushers 11 for placing and pushing protective embolic agents; the embolism rescue component is a rescue syringe for placing and pushing physiological saline, which accelerates the liquefaction of the protective embolic agent and has the effect of rescuing the embolic blood vessels and restoring their patency; the microcatheter is detachably connected to the pusher and the rescue syringe.
[0106] Usually at least one pusher is selected, preferably 2-3. In a specific embodiment of the present invention, three pushers are selected, namely a first pusher, a second pusher, and a third pusher. The pusher and rescue syringe are selected as ring-handle screw-mouth syringes, and the empty barrel of the syringe is marked with a scale showing the volume of the liquid in the barrel. The structural schematic diagram of the pusher is shown in FIG. Figure 3 As shown in FIG. 1 , the microcatheter is a super-selective microcatheter, i.e., a super-selective microcatheter used in interventional treatment. The tail end of the microcatheter has a thread.
[0107] The microcatheter is connected to the injector and the rescue syringe by threads. During the interventional treatment, the superselected microcatheter tip is superselected to the non-lesion supplying artery that needs temporary protection through the vascular superselection technology, and the first, second or third injector of the injection assembly is connected to the microcatheter to inject the protective embolic agent. The protective embolic agent in a semi-gel state in the first, second or third injector is injected to the non-target blood vessel that needs temporary blockage during the interventional treatment. The semi-gel embolic agent forms a gel in the blood vessel to embolize the blood vessel, preventing chemotherapy drugs and embolic materials from entering the non-target blood vessels of the interventional treatment, thereby achieving a short-term, protective embolism. When the conventional chemoembolization operation is successfully completed (i.e., the conventional chemoembolization operation is shorter than 15 minutes), the vascular superselection technology is used again to superselect the microcatheter tip to the non-target blood vessel during the interventional treatment. The embolism rescue syringe is connected to the microcatheter tail end thread through the screw mouth at the proximal end of the temporary blockage of the blood vessel; then, under fluoroscopy, it is determined that the tip of the microcatheter is located at the temporary blockage position in the non-lesion supply artery, and normal saline is slowly injected to inject the low-temperature (below 37°C) normal saline into the blockage position of the protective embolic agent to accelerate the liquefaction of the protective embolic agent gel, so that the blocked blood vessel is unobstructed, blood flow is restored in a short time, and ischemic damage to non-target areas is avoided; or during the interventional surgery, if the protective embolic agent is injected too much or the blockage site is not good, the microcatheter is super-selected to the proximal end of the plug, the embolism rescue syringe is connected to the microcatheter tail end thread through the screw mouth, and normal saline is injected to accelerate the liquefaction of the embolic agent blocking the blood vessel cavity, relieve the embolism, restore blood flow, and avoid damage.
[0108] The sizes and shapes of the first, second and third injectors in the present invention may be the same or different, but since the diameters of the blood vessels to be protected by embolization are different, a 2 ml syringe is more often used when delicate operations are required. However, for blood vessels with thicker diameters, a 5 ml syringe is required. Usually, the first injector has a 5 ml ring-handle screw-mouth syringe, and the second and third injectors have a 2 ml ring-handle screw-mouth syringe. The injector is detachably connected to the third connecting branch of the connector, and the injector is threadedly connected to the third connecting branch.
[0109] The first, second and third pushers and rescue syringes are ring-handle screw-mouth syringes, and the syringes are respectively provided with corresponding scales for marking the volume of the liquid in the barrel. The first, second and third pushers and rescue syringes have the same structure and shape, and only the volume size is different.
[0110] 3. The heat preservation component is used to heat and keep the uniformly mixed protective embolic agent warm, so that the uniformly mixed protective embolic agent remains in a semi-gel state.
[0111] The physiological saline for liquefying and rescuing embolism is placed in a heat preservation component and refrigerated to keep the physiological saline at a low temperature, below 37°C, preferably 2-8°C, and more preferably 5±0.5°C.
[0112] The insulation component includes a heating-insulation box 5 with heating and insulation functions, and a refrigeration box with refrigeration function. The pusher of the injection component is placed in the heating-insulation box, and the pusher is heated and insulated so that the protective embolic agent placed in the pusher is maintained at the phase change temperature; the embolic rescue part of the injection component is placed in the refrigeration box so that the embolic rescue part is maintained at a low temperature or room temperature.
[0113] like Figure 4 , 5 The heating-insulation box includes a box body 51, a partition 53 and an electric heating element 54. The box body is a closed body with a cavity and has a sealing cover 52 that can be opened and closed. The box body is lined with insulation material, and the sealing cover is lined with insulation material on the side facing the partition; the partition is set on the top of the box body (such as Figure 4 ), a heating chamber 55 is formed between the box body and the lower part of the partition, and an electric heating element is arranged in the heating chamber formed by the box body and the partition, and the electric heating element is equipped with an electronic heating temperature controller 56, such as Figure 6 The electric heating element is connected to the electronic heating thermostat through a wire, and the electronic heating thermostat is arranged in the heating chamber. The electronic heating thermostat adopts an intelligent temperature controller, and the electric heating element is an existing and known heating device in the art, such as an electric heating tube, a heating wire, a resistance wire, an electric heating pad, etc. All electric heating elements known in the art are applicable to the present invention.
[0114] In another embodiment, a partition is arranged inside the box body to separate the box body into two parts, such as Figure 5 .
[0115] The partition 53 of the heating-insulation box is provided with three grooves for placing and fixing the injection assembly pushers, namely the first pusher groove 7, the second pusher groove 8 and the third pusher groove 9, which are used to place the first, second and third pushers respectively. The grooves are embedded in the partition and extend toward the heating chamber. The shape and size of the grooves for placing the pushers match the shape and size of the pushers and the second pushers respectively. The electric heating elements are evenly distributed in the adding chamber to ensure uniform heating.
[0116] The heating-insulating box is small in size and easy to carry. It has a plug connected to an external power supply. After being connected to the external power supply, it provides power to the heating-insulating box, or a battery is used to power the heating-insulating box. The electronic heating thermostat can ensure that the temperature in the enclosed space inside the heating-insulating box is constant and controlled within an appropriate range (37-38°C). The temperature of the intelligent temperature controller is controllable with an accuracy of 0.1°C. After the heating-insulating box is connected to the power supply, the injection assembly placed inside the box is heated and the temperature inside the box is kept constant. The heating-insulating box can adjust the heating and insulation temperature of the heating-insulating box at any time according to the needs of use; and after the temperature of the heating-insulating box is set, the temperature inside the box is kept within the range of ±0.5°C. For example, if the heating temperature is set to 37°C, the temperature of the heating-insulating box is kept at 37.0±0.5°C after heating, and the other temperatures are similar.
[0117] In the specific method of the present invention, the heating and insulation temperature of the heating-insulating box is adjusted to 37.0±0.5℃.
[0118] The refrigerator is a medical refrigerator, and the refrigeration temperature is 2-8° C., preferably 5±0.5° C. The refrigerator adopts chip refrigeration technology (semiconductor refrigeration / electronic refrigeration).
[0119] A rescue syringe is placed in the cavity of the refrigerator; a refrigerated partition can also be placed in the cavity of the refrigerator, and the refrigerated partition has a rescue syringe groove for placing and fixing the rescue syringe, and the size and shape of the rescue syringe groove match the size and shape of the rescue syringe.
[0120] All existing and known refrigerators in the art are applicable to the present invention. All medical refrigerators in the art are applicable to the present invention, and usually a medical refrigerator with a temperature of 2-8°C is selected, such as a refrigerator for biological preparations such as insulin and interferon; a small portable insulin refrigerator, etc. For example: SAST intelligent temperature-controlled insulin refrigerator.
[0121] The first, second and third injectors injected with protective embolic agent are placed in corresponding grooves in the heating-insulation box of the insulation component, powered on, heated, and maintained at 37.0±0.5℃ for 2-3 minutes to make the mixed protective embolic material in a semi-gel state.
[0122] The heating-insulating box in the present invention is a temperature-controlled box with heating and heat preservation functions. After being connected to an external power source through a plug (not shown in the drawings), the heating-insulating box is powered to heat the injector of the injection assembly, so that the protective embolic agent in the injector is heated and maintained at a temperature of 37.0±0.5°C, so that the protective embolic material is in a semi-gel state. The refrigerator in the present invention is a medical refrigerator, which maintains a temperature of 5±0.5°C, so that the temperature of the physiological saline placed in the rescue syringe placed in the refrigerator is maintained at 5±0.5°C.
[0123] The working principle (i.e., working process) of the injection device for the protective embolic agent through the vascular cavity of the present invention is as follows:
[0124] Before interventional treatment, the location of the blood vessel to be blocked is first determined by imaging methods, and the dose of embolic material to be used is estimated based on the vascular morphology, diameter and length.
[0125] 1. At room temperature, the temperature-sensitive phase change material (20% poloxamer 407 aqueous solution) and the fluoroscopic developer (iohexol injection) are sucked into the first mixer 1 and the second mixer 2 respectively, and then the injection connector of the screw-mouth syringe of the first mixer is threadedly connected to the first connecting branch 31 of the connecting piece 3, and the injection connector of the screw-mouth syringe of the second mixer is threadedly connected to the first connecting branch 32 of the connecting piece 3, and fixed together;
[0126] 2. Thread the injection connector of the first, second or third injector (screw-type syringe) of the injection assembly to the third connecting branch 33 of the connecting member 3;
[0127] 3. Turn the valve 4 on the third connecting branch pipe to connect the third connecting branch pipe to the first, second or third injector of the injection assembly; at the same time, push the first and second mixers to inject the temperature-sensitive phase change material (20% poloxamer 407 aqueous solution) and the fluoroscopic developer (iohexol injection) in the mixing assembly into the connecting piece in a ratio of (4:1), pass through the third connecting branch pipe, mix well, and form a protective embolic agent; the well-mixed protective embolic agent flows into the first, second or third injector of the injection assembly;
[0128] 4. After the embolic agent injected into the pusher reaches the injection dose required for the operation, turn and close the valve 4, so that the passage between the third connecting branch of the connecting assembly and the first, second or third pusher is closed, and then the first, second or third pusher is removed from the third connecting branch to seal the syringe head;
[0129] 5. Place the first, second or third injector injected with the protective embolic material in the heating-insulation box of the insulation component and in the corresponding groove, turn on the power, heat it, heat it up and keep the temperature at 37.0±0.5℃, the protective embolic material in the first, second or third injector of the injection component changes from liquid to semi-gel state and keeps it in semi-gel state; usually after heating for 3 minutes, it can be confirmed that the mixed embolic agent is in semi-gel state;
[0130] The present invention fills the gap in the current protective embolization technology in the field of intravascular interventional treatment, and relying on this material, the clinical application of the concept of "protective embolization" becomes possible in the near future. The problem of the stable state of transient embolic agents has been solved. Animal experiments have shown that Poloxamer 407 is a unique temperature-sensitive in-situ gel material. It is liquid at low temperatures, and quickly converts to a colloidal state when the temperature rises to the phase transition temperature. It can be converted back to a liquid state when the temperature drops or in the body, and its colloidal properties are used to complete embolism.
[0131] The heating-insulating box of the device of the present invention is used to place the uniformly mixed protective embolic agent in the insulation component before interventional treatment, heat the uniformly mixed protective embolic agent to 37.0±0.5°C to form a semi-gel state, and then directly push-inject. The embolic agent is in a semi-gel state during the push-in process, the push-in is smooth, the dosage is accurate, and the push-in position, that is, the embolic position, is accurate.
[0132] 6. During the interventional procedure, the superselected microcatheter tip of the injection component is superselected to the non-lesion supplying artery that needs temporary protection through the vascular superselection technology, and the blood flow is ensured to be smooth; then the first, second or third injector of the injection component, which is heated and maintained at a temperature of 37.0±0.5℃, is taken out from the insulation component and threadedly connected to the microcatheter tail end through the screw port; then, after confirming under fluoroscopy that the microcatheter tip is located in the non-lesion supplying artery that needs protection, the semi-gel embolic agent is slowly injected into the non-target blood vessel that needs to be temporarily blocked by the interventional treatment through imaging methods, and a short-term, protective embolization is performed to prevent chemotherapy drugs and embolic materials from entering the non-target blood vessels of the interventional treatment;
[0133] 7. When the conventional chemoembolization operation is successfully completed (i.e., the conventional chemoembolization operation is shorter than 15 minutes), the vascular superselection technology is used again to superselect the tip of the microcatheter to the proximal end of the temporary blockage position of the non-target blood vessel during the interventional treatment, and the embolism rescue syringe is taken out from the refrigerator (5±0.5℃) of the insulation component and connected to the microcatheter tail thread through the screw mouth; then, under fluoroscopy, it is determined that the tip of the microcatheter is located at the temporary blockage position in the non-lesion supplying artery, and normal saline is slowly pushed in to inject the low-temperature (5±0.5℃) normal saline into the blockage position of the protective embolic agent, accelerate the liquefaction of the protective embolic agent gel, make the blocked blood vessel unobstructed, restore blood flow in a short time, and avoid potential ischemic damage to the non-target area.
[0134] Alternatively, during the interventional procedure, if the protective embolic agent is injected too much or the occlusion site is not good, the microcatheter is super-selected to the proximal end of the rubber plug, and a rescue syringe filled with ice / room temperature saline is taken out from the refrigerator (5±0.5℃) of the insulation component, connected to the tail end of the microcatheter through the screw port at the head end, and normal saline is injected to accelerate the liquefaction of the embolic agent blocking the blood vessel cavity, relieve the embolism, and restore blood flow;
[0135] Alternatively, an embolism rescue syringe filled with saline at room temperature can be directly connected to the threaded end of the microcatheter via the screw thread; then, under fluoroscopy, it is confirmed that the tip of the microcatheter is located at the temporary blockage site in the non-lesion supplying artery, and saline is slowly pushed in to inject the saline at room temperature into the blockage site of the protective embolic agent, thereby accelerating the liquefaction of the protective embolic agent gel, unblocking the blocked blood vessels, restoring blood flow, and avoiding ischemic damage to non-target areas.
[0136] Although the embodiments of the present invention have been shown and described above, it is to be understood that the above embodiments are exemplary and are not to be construed as limitations on the present invention. A person skilled in the art may change, modify, replace and modify the above embodiments within the scope of the present invention without departing from the principles and intent of the present invention.
Claims
1. A device for injecting a protective embolic agent into a blood vessel cavity, characterized in that: It includes mixing components, insulation components and injection components, among which: The mixing assembly comprises two mixers and a connector, wherein the connector comprises three connecting branches, and the three connecting branches are interconnected; wherein the connecting ends of the first and second connecting branches are detachably connected to the two mixers respectively, and the connecting end of the third connecting branch is detachably connected to the injection assembly; and the first mixer of the two mixers is used for placing the temperature-sensitive phase change material; and the second mixer is used for placing the fluoroscopic developer, and is used for mixing the temperature-sensitive phase change material and the fluoroscopic developer to form a protective embolic agent; The heat preservation component includes a heating-insulation box and a refrigeration box with heating and heat preservation functions; it is used to heat and keep the uniformly mixed protective embolic agent warm, so that the protective embolic agent remains in a semi-gel state; The injection assembly includes a pusher and an embolism rescue component. The pusher includes at least one pusher for placing and pushing a protective embolic agent. The embolism rescue component is a rescue syringe for placing and pushing physiological saline. The injection assembly is used to push the protective embolic agent in a semi-gel state into the blood vessel cavity that needs to be temporarily blocked, temporarily blocking the blood vessel and playing a protective embolism role; push the physiological saline into the blood vessel cavity that has been protectively embolized, add the protective embolic agent to convert it into a liquid state and release the embolism; The pusher of the injection assembly is placed inside a heating and insulation box, and the embolism rescue syringe of the injection assembly is placed in a refrigerator.
2. The injection device according to claim 1, characterized in that: The two mixers are screw-mouth syringes or disposable medical syringes.
3. The injection device according to claim 1, characterized in that: The two mixers are screw-mouth type syringes.
4. The injection device according to claim 1, characterized in that: The connecting piece is a three-way connecting pipe in a "Y" shape or a "T" shape.
5. The injection device according to claim 1, characterized in that: A valve is arranged near the end of the third connecting branch of the connecting member to control the flow direction of the protective embolic agent formed by mixing the temperature-sensitive phase-change material and the fluoroscopic developer in the first and second mixers.
6. The injection device according to claim 1, characterized in that: The interior of the heating-insulating box is provided with a partition, and at least one groove is arranged on the partition, and the groove is embedded in the partition for accommodating and placing the pusher of the injection assembly.
